Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA-317 in CD7-positive Refractory/Relapsed Acute Leukemia
NCT04785833Phase 1Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA3-17 in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by PersonGen BioTherapeutics. Primary endpoint: Dose Limiting Toxicity at 2 years. Status: unknown.
02
Drugs
PA3-17
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT04785833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04785833.